Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT

Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT

Abstract Allogenic hematopoietic stem cell transplantation (allo‐HCT) is the standard treatment for acute myeloid leukemia (AML) in non‐complete remission (non‐CR); however, the prognosis is inconsistent. This study aimed to develop and validate nomograms and a web application to predict the overall...

Full description

Bibliographic Details
Main Authors: Shigeki Hirabayashi, Ryuji Uozumi, Tadakazu Kondo, Yasuyuki Arai, Takahito Kawata, Naoyuki Uchida, Atsushi Marumo, Kazuhiro Ikegame, Takahiro Fukuda, Tetsuya Eto, Masatsugu Tanaka, Atsushi Wake, Junya Kanda, Takafumi Kimura, Ken Tabuchi, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada, Shingo Yano
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Cancer Medicine
Subjects:
acute myeloid leukemia
hematopoietic stem cell transplantation
nomogram
non‐complete remission
web application
Online Access:https://doi.org/10.1002/cam4.3920

Internet

https://doi.org/10.1002/cam4.3920

Similar Items